Blue Jet Healthcare · risk themes across the available quarters.
Bear-case history
Management acknowledged destocking and supply chain realignment for bempedoic acid, but did not quantify the impact or confirm when volumes will normalize. Analyst raised concern about potential permanent loss of market share.
Gross margin fell to 52% in Q3 due to product mix and a 1% inventory write-off. Management guided a wide 50-55% range, indicating uncertainty.
Despite diversification efforts, a significant portion of revenue still depends on a few molecules, making the company vulnerable to order lumpiness.
The large greenfield capex may strain cash flows; management mentioned options including debt or equity dilution, but no firm plan was provided.